MANUFACTURING ARTICLES
-
![fundamental comparison metaphor or analogy-GettyImages-2191773530]( "Comparing Advanced Modality Needs, Part 1: Manufacturing")
Comparing Advanced Modality Needs, Part 1: ManufacturingADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.
-
![Future-GettyImages-834713748]( "Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions")
Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future DirectionsThis last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.
-
![Action Plan-GettyImages-2249288072]( "Antibody–Oligonucleotide Conjugates, Part 2: Manufacturing")
Antibody–Oligonucleotide Conjugates, Part 2: ManufacturingLet's delve into manufacturing strategy, conjugation chemistry, process development and scale-up, and purification: the central manufacturing challenge.
-
![Financial security, wealth protection, money insurance-GettyImages-2288391875]( "Protecting The Platform: Trade Secret Protection For RNA Biotech Companies")
Protecting The Platform: Trade Secret Protection For RNA Biotech CompaniesAs RNA therapeutics grow more complex and collaborative, trade secrets are becoming an increasingly important part of protecting valuable platform innovation.
-
![creativity, innovation-GettyImages-2209122228]( "Engineering RNA Agonists For Systemic Immunity Without Systemic Toxicity")
Engineering RNA Agonists For Systemic Immunity Without Systemic ToxicityKrieg believes the answer lies in a deeper understanding of innate immune biology and the design of RNA/DNA hybrid mimics of viral RNA and DNA that are detected by innate immune receptors.
-
![economy law of supply and demand-GettyImages-1263079550]( "Is mRNA Manufacturing Overbuilt?")
Is mRNA Manufacturing Overbuilt?mRNA pipelines continue to advance, but has provider growth outpaced the pipeline? Let's take a closer look.
MANUFACTURING VIDEOS
This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.
Advance from development to manufacturing with expert-led, hands-on, or virtual courses that strengthen process understanding and scale-up skills designed to support every stage of your molecule’s journey.
Cytiva is just about that initial oligo synthesis right? Wrong! Find out all about the synthesis systems friends and family across the full oligo workflow.
Discover how early choices in oligo synthesis workflows shape performance. Learn what to consider across design, reagents, and system optimization to build a process ready for smooth scale‑up.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1335381149- MRNA, Vaccine]( "Review Of mRNA Vaccines & Therapeutics Manufacturing Challenges")
Learn more about the challenges that arise during the synthesis, purification, and encapsulation of mRNA.
-
![Gene therapy data GettyImages-1054555460]( "Let The Future Start Today: Development Of Better LNP-Based Genetic Medicines")
Discover how you can accelerate the time to patients for new vaccines and therapies with innovative, streamlined technology that is quicker and more intuitive.
-
![Multivariate Inter-Stage Batch Profile Monitoring Feature]( "Multivariate Inter-Stage Batch Profile Monitoring And Future State Estimation")
How much quicker and easier would it be if we could know the process’s health by looking at a single metric rather than checking hundreds of parameters?
-
Breaking down the implementation of continuous manufacturing into the following four steps may provide some much-needed guidance as you prepare your network for the future of biomanufacturing.
-
![viral clearance services]( "Choosing A CDMO That Can Grow With A Viral Program")
Viral modalities demand more from CDMO selection: relevant experience, rigorous tech transfer, analytical readiness, and a clear path to scale matter more than equipment alone.
-
![scientist laboratory research iStock-942266140]( "How Data Analytics Accelerates Transition To Bioprocessing 4.0")
Following successful Industry 4.0 implementation in the automotive, communications, aerospace, and other industries, the biopharma industry is now joining the digital revolution.
-
![GettyImages-1310024666-genetic-digital-dna]( "How Nanoparticle Platforms Are Unlocking Genetic Medicine's Potential")
Explore how the HIT SCAN platform accelerates gene therapy delivery by screening polymeric nanoparticles, enhancing precision and regulatory pathways for next-generation genetic medicines.
